SAN DIEGO, CA, USA I 11, 2024 I AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology ...

WILMINGTON, DE, USA I 11, 2024 I Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) ...

BOSTON, MA, USA I 11, 2024 I Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced ...

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway ...

ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...

Phase 1/2 study initiated for ATX-559, a first-in-class inhibitor of DHX9, focused on patients with BRCA1/2-deficient breast cancer and MSI-H and/or dMMR ...

TOKYO, USA & NOVI, MI, USA & DÜSSELDORF, Germany I 11, 2024 I Asahi Kasei Pharma has taken another step in its transformation into a global ...

Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease ...

STOCKHOLM, Sweden I 10, 2024 I Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the ...

COPENHAGEN, Denmark I 10, 2024 IZealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery ...

PANGYO, South Korea I 10, 2024 I Huonslab, a subsidiary of Huons Global (KOSDAQ: 084110), announced today the successful enrollment and ...

EKZ-102 is in IND-enabling development for the treatment of ALS and other neurodegenerative diseases, with a first-in-human clinical study planned for 2025 ...